Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.

Lapointe, Marc-Olivier; Caru, Maxime; Curnier, Daniel; Raboisson, Marie-Josée; Andelfinger, Gregor; Krajinovic, Maja; Laverdière, Caroline; Sinnett, Daniel; Périé, Delphine

Lapointe, Marc-Olivier; Caru, Maxime; Curnier, Daniel; Raboisson, Marie-Josée; Andelfinger, Gregor; Krajinovic, Maja; Laverdière, Caroline; Sinnett, Daniel; Périé, Delphine.

Afiliación

Lapointe MO; Department of Mechanical Engineering, Polytechnique.
Caru M; Sainte-Justine University Health Center, Research Center.
Curnier D; Department of Mechanical Engineering, Polytechnique.
Raboisson MJ; Sainte-Justine University Health Center, Research Center.
Andelfinger G; Sainte-Justine University Health Center, Research Center.
Krajinovic M; School of Kinesiology and Physical Activity Sciences, Faculty of Medicine.
Laverdière C; Sainte-Justine University Health Center, Research Center.
Sinnett D; Sainte-Justine University Health Center, Research Center.
Périé D; Department of Pediatrics, University of Montreal, Montreal, QC, Canada.

J Pediatr Hematol Oncol ; 45(2): 70-77, 2023 03 01.

Article en En | MEDLINE | ID: mdl-36161876

Asunto(s)

Dexrazoxano; Leucemia-Linfoma Linfoblástico de Células Precursoras; Disfunción Ventricular Izquierda; Humanos; Volumen Sistólico; Función Ventricular Izquierda; Doxorrubicina; Sobrevivientes; Cardiotoxicidad

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Disfunción Ventricular Izquierda / Leucemia-Linfoma Linfoblástico de Células Precursoras / Dexrazoxano Límite: Humans Idioma: En Revista: J Pediatr Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google